Manufacturing lines handling (S)-α,α-diphenyl-3-pyrrolidineacetamide L-tartrate routinely observe a critical inflection point during downstream hydrobromide salt formation: the diastereomeric purity of the tartrate salt directly governs the rejection efficiency of the corresponding (R)-enantiomer in the final Darifenacin hydrobromide crystallization. The use of 1.05–1.15 molar equivalents of L-tartaric acid against the racemic free base in a 4:1 (v/v) ethanol/water system at 65–70°C, followed by controlled cooling to 0–5°C with a ramp rate not exceeding 3°C/h, has been shown in pilot-plant batches to yield (S)-enantiomeric excess consistently above 99.5%. Residual ethanol in the isolated salt must be driven below 500 ppm via tray drying at 40°C under 25 mbar for not less than 12 hours, as higher solvent levels interfere with the subsequent N-alkylation step by promoting side product formation with the dihydrobenzofuranethyl electrophile. Throughout this resolution sequence, compliance with ICH Q7 Section 8.3 (recovery of materials and solvents) and 21 CFR Part 211.84 (testing and approval of components) is mandated, with in-process controls requiring chiral HPLC monitoring per Ph. Eur. 2.2.29 and the specification for the tartrate salt set at ≥ 99.0% chemical purity and ≥ 99.5% optical purity. The crystallized intermediate, after neutralization with aqueous sodium hydroxide to liberate the free base, is taken into the N-alkylation stage where it reacts with a 1.0–1.05 molar equivalent of a suitably activated 2-(2,3-dihydrobenzofuran-5-yl)ethyl derivative in acetonitrile under reflux (80–82°C) for 18–22 hours; the crude product is subsequently converted to Darifenacin hydrobromide, a selective M3 muscarinic receptor antagonist formulated in extended-release tablets at doses of 7.5 mg and 15 mg for the management of overactive bladder. Operationally, the tartrate salt’s narrow solubility window—precipitating effectively only between pH 4.8 and 5.2—demands inline pH probes rather than periodic sampling, a lesson drawn from several commercial campaigns where batch-to-batch optical purity drifted outside the 99.0% threshold when manual adjustments lagged behind nucleation kinetics.
Why does this L-tartrate salt remain the preferred pre-split intermediate rather than the free base or the hydrobromide?
The answer lies in the robustness of diastereomeric salt resolution when pKa differentials are modest. The (S)-free base exhibits a pKa (conjugate acid) near 9.2, while the corresponding (R)-isomer differs by less than 0.2 log units, rendering classical extraction-based separation ineffective. By contrast, the L-tartrate salt leverages a lattice energy disparity of approximately 4–6 kJ/mol between (S)- and (R)-diastereomeric salts—sufficient to achieve a single-crop enrichment from racemate to ≥ 99% e.e. when the crystallization solvent polarity is tuned to a dielectric constant between 24 and 30 (e.g., ethanol/water mixtures). This process step is governed by ICH Q6A Decision Tree #3 regarding the setting of acceptance criteria for chiral new drug substances, and the salt itself is typically released against an internal specification that mirrors EP monograph 01/2024:2617 for a related pyrrolidine derivative. The addition ratio of L-tartaric acid to racemic 3-pyrrolidineacetamide free base is locked at 1:1 stoichiometry; deviations beyond ±2 mol% generate metastable mixed crystals incorporating both enantiomers, which later manifest as a 0.5–1.2% (R)-impurity burden that cannot be purged during hydrobromide finishing. In the downstream alkylation, the neutralized free base is combined with the electrophile at a mass loading of approximately 68–72 wt% relative to the total reaction mass, and process analytical technology (PAT) tools—specifically ReactIR probes tracking the disappearance of the secondary amine stretch at ~3300 cm⁻¹—are deployed to define the endpoint instead of fixed hold times, a practice that reduced batch cycle time by 25% in a 2000 L glass-lined reactor validated under EU GMP Part II. The terminal dosage form, Darifenacin hydrobromide extended-release tablets, must conform to USP <711> dissolution criteria and ICH Q3B(R2) thresholds for unspecified impurities held below 0.10%.
Process mass intensity benchmarks across telescoped N-alkylation sequences
When the (S)-α,α-diphenyl-3-pyrrolidineacetamide L-tartrate is employed as the direct starting material—dispensing with prior neutralization—the telescoped process in acetonitrile under potassium carbonate slurry conditions exhibits a process mass intensity (PMI) of 18–22 kg input per 1 kg of liberated free base equivalent, driven primarily by the need for 8–10 volumes of solvent relative to the salt mass. This figure contrasts with a PMI near 12–15 kg/kg when the pre-isolated free base is used, yet many contract manufacturing organizations retain the salt route to avoid the elevated D-amphetamine-like handling precautions mandated by ECHA Regulation (EC) No 1272/2008 for the free amine under CMR assessment. The salt is charged into the reactor at a ratio of 1.0 molar equivalent with respect to the alkylating agent, with the latter being a mesylate or a bromide derivative of the dihydrobenzofuranethyl moiety; excesses beyond 1.05 eq. trigger dialkylation at the pyrrolidine nitrogen, forming a quaternary ammonium impurity specified below 0.15% per the drug substance impurity profile described in the EMA’s published assessment report for the originator product. The heterogeneous mixture is agitated with a retreat-curve impeller at 120–140 rpm in a vessel with a 1.5:1 liquid height-to-diameter ratio to avoid vortex-induced stratification of potassium carbonate fines. Following 20 ± 2 hours at 80 ± 2°C, the reaction mass is filtered hot through a 5-micron sparkler filter coated with diatomaceous earth; failure to maintain the filtrate temperature above 65°C leads to premature precipitation of the coupled product, causing yield losses of 7–10% and elevated levels of the des-alkyl pyrrolidine impurity in the mother liquor. The filtered product stream is then subjected to hydrobromic acid in isopropanol to furnish Darifenacin hydrobromide, the active ingredient in a once-daily prolonged-release tablet that utilizes a hydrophilic matrix of hydroxypropyl methylcellulose (Methocel K100M) to achieve a 24-hour release profile, all produced under ISO 13485:2016 for combination product components where applicable. The entire synthesis sequence adheres to ICH Q11 Sections 5.1–5.2 regarding the selection of starting materials and the control strategy for mutagenic impurities, with alkylating agent purge factors validated to exceed 4.5 log reduction.
A chemically hygroscopic junction point arises when the L-tartrate salt is stored in non-climate-controlled warehouses above 60% relative humidity. Under these conditions, water uptake exceeds 1.5 wt% within 48 hours, leading to partial deliquescence that compromises the stoichiometric integrity of the salt and introduces variability into the N-alkylation charge. Gravimetric vapor sorption analysis conducted at 25°C between 0% RH and 90% RH reveals a critical threshold at 58% RH where the mass change crosses 0.5%; consequently, the material is double-bagged in aluminum-lined low-density polyethylene with a desiccant load of ≥ 200 g silica gel per 25 kg drum when destination ports are subject to tropical maritime transit. This storage stipulation is codified in the supplier’s technical dossier referencing ASTM D7702-14 for primary drying loss methodology. In the downstream formulation space, the tartrate counterion itself does not persist into the final drug product—it is removed during the free-basing step—but its presence as a crystalline lattice partner ensures that the pyrrolidine nitrogen remains protected from oxidative degradation during prolonged storage, as confirmed by forced degradation studies at 40°C/75% RH for 6 months showing total related substances increase by less than 0.2% versus 1.1% for the free base under identical conditions. Adherence to 21 CFR 211.165 (testing and release for distribution) requires that every batch of the salt leaving the contract manufacturing facility is accompanied by a certificate of analysis listing enantiomeric purity, residual ethanol, water content, and optical rotation [α]D²⁰ in methanol at c = 1.0, with the acceptance range set at +28.0° to +30.5°. The terminal Darifenacin hydrobromide tablets, identifiable by National Drug Codes in regulated markets, are manufactured on high-speed rotary presses with a main compression force of 8–12 kN and a pre-compression force of 2–4 kN to achieve a target hardness of 80–120 N without compromising the hydrophilic matrix integrity.
Regulatory mapping for ANDA filers referencing the tartrate pathway
Generic drug developers who adopt the (S)-α,α-diphenyl-3-pyrrolidineacetamide L-tartrate as their registered starting material under a DMF Type II must align the specifications of this intermediate with the originator’s confidential part of the drug master file and the requirements of FDA Guidance for Industry “ANDAs: Stability Testing of Drug Substances and Products” (June 2013). A comparative matrix of essential quality attributes is often used to bridge the tartrate salt’s controls to the hydrobromide API’s critical quality attributes; a fragmented view of such a matrix appears below, restricted to the three most scrutinized parameters that impact bioequivalence study design.
| Attribute | (S)-Tartrate Acceptance Criterion | Corresponding Darifenacin Hydrobromide Criterion | Governing Standard |
|---|---|---|---|
| Chiral purity | (R)-enantiomer ≤ 0.5% by chiral HPLC | (R)-isomer ≤ 0.3% (to maintain M3 selectivity ratio) | USP 〈621〉, EP 2.2.29 |
| Residual solvents | Ethanol ≤ 500 ppm, acetonitrile ≤ 410 ppm | Cumulative Class 2 solvents ≤ 2.9 mg/day per ICH option 2 | ICH Q3C(R8), USP 〈467〉 |
| Heavy metals | Pd ≤ 10 ppm, Ni ≤ 5 ppm (catalyst carryover risk) | Elemental Class 1 metals per oral PDE; sum ≤ 20 µg/day | ICH Q3D Guideline, USP 〈232〉/〈233〉 |
Process validation batches executing the downstream conversion—from tartrate salt to final tablet—are expected to meet a process capability index (Cpk) of at least 1.33 for the hydrobromide content uniformity (95.0–105.0% label claim), where variability in the alkylation step traced back to residual water in the tartrate salt was identified as the dominant root cause in a retrospective multivariate analysis of 42 industrial batches. Tightening the salt’s water specification from ≤ 1.0% to ≤ 0.5% (Karl Fischer, ASTM E203) reduced the lot-to-lot standard deviation of the API assay from 1.8% to 0.9%. Such refinements are enacted under the change control provisions of ICH Q10 Section 3.2 and communicated to downstream regulatory holders via annual reports to Division of Filing Review (HFD-640).
When residual pyrrolidine byproducts compromise the dissolution profile of extended-release matrices
A single unexplained dissolution failure in a 7.5 mg biobatch led to the identification of a trace amine impurity—tentatively characterized as des-alkyl (S)-α,α-diphenyl-3-pyrrolidineacetamide—which co-crystallizes with the hydrobromide API when the preceding tartrate salt carries over ≥ 0.8% of ring-opened or de-benzylated progenitors from an over-heated resolution step. The phenomenon is observable only in media with pH 6.8 phosphate buffer, where the protonated impurity forms a poorly soluble interfacial film on the hydrating HPMC matrix, retarding drug release at the 4-hour time point by 15–20% relative to control. The corrective action, validated across three consecutive commercial lots, introduced a hot acetonitrile trituration of the tartrate salt at 50°C for 2 hours with a 3:1 (v/w) solvent-to-solid ratio prior to neutralization, which reduced the undesired pyrrolidine-related substances to ≤ 0.10% as measured by HPLC using a C18 column (250 × 4.6 mm, 5 µm) and a gradient of 0.1% trifluoroacetic acid/acetonitrile at 1.0 mL/min, with UV detection at 210 nm. This purification is conducted under ISO 14001:2015-certified emission controls because the acetonitrile distillate stream requires recovery via fractional distillation achieving ≥ 99.5% purity for reuse. The operating range for the trituration step includes a stir rate of 180–220 rpm using a pitched-blade turbine in a 1000 L vessel, and material of construction must be 316L stainless steel passivated with citric acid to avoid iron-mediated discoloration of the tartrate salt. The final drug product, Darifenacin hydrobromide prolonged-release tablets in 7.5 mg and 15 mg strengths, is blister-packaged in PVC/PVDC/Alu cold-form foil under 21 CFR 211.132 tamper-evident requirements, with each batch undergoing dissolution testing per USP Apparatus 2 (paddle, 50 rpm, 900 mL media) across an 18-point sampling schedule to demonstrate conformance with the originator’s f2 similarity criterion of ≥ 50.
An alternative path exploits the tartrate salt not as an intermediate but as an analytical reference for impurity tracking. Here, the substance is dissolved at a concentration of 0.5 mg/mL in methanol and injected as a system suitability solution under ICH Q2(R1) validation parameters, where the L-tartrate peak must resolve from the free base’s homologous impurity with a resolution factor Rs ≥ 2.0. Laboratories maintaining ISO/IEC 17025:2017 accreditation use the salt to calibrate evaporative light scattering detectors (ELSD) for non-UV-absorbing counterion quantification, a niche application that demands addition of the standard at 1.0% (w/w) of the test sample mass. In this quality control context, the “production process” is the preparation of a certified reference material under ISO Guide 34, and the “end product” is a certificate reporting traceability to the SI unit of mass through a hierarchy of balances calibrated per OIML R 111. The material’s water content is determined coulometrically by Karl Fischer titration using Hydranal-Coulomat AG reagent, and the assigned purity 99.7% ± 0.4% (k = 2) accounts for residual inorganic species verified by sulfated ash testing at 600°C per EP 2.4.14.
